Piper Jaffray Companies set a $26.00 target price on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a research report report published on Thursday, October 19th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a buy rating in a report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a report on Thursday, August 3rd. Zacks Investment Research upgraded Vanda Pharmaceuticals from a hold rating to a buy rating and set a $18.00 price objective for the company in a report on Wednesday, October 18th. Jefferies Group LLC restated a buy rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of Buy and an average target price of $21.29.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 14.70 on Thursday. The company’s 50-day moving average price is $17.08 and its 200 day moving average price is $15.77. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.99. The company’s market cap is $659.41 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter last year, the company posted $0.01 earnings per share. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities analysts forecast that Vanda Pharmaceuticals will post ($0.43) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/10/29/vanda-pharmaceuticals-inc-vnda-given-a-26-00-price-target-at-piper-jaffray-companies.html.
Several hedge funds have recently modified their holdings of VNDA. Legal & General Group Plc boosted its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $196,000. American International Group Inc. boosted its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares during the period. Voya Investment Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 4,605 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its stake in shares of Vanda Pharmaceuticals by 46.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 6,487 shares during the period. Institutional investors and hedge funds own 86.45% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.